ClearPoint Neuro (NASDAQ:CLPT) Sets New 1-Year High - Time to Buy?

Key Points

• ClearPoint Neuro's shares reached a new 52-week high of $29.87, closing at $29.60 with a trading volume of over 1.3 million shares.
• Analyst ratings show a consensus of "Moderate Buy" with a price target of $19.67, reflecting a mix of optimism and caution among financial analysts.
• The company reported a quarterly loss of ($0.21) per share, slightly missing analyst expectations, despite revenues of $9.22 million, which matched estimates.

ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) shares reached a new 52-week high on Thursday . The company traded as high as $29.87 and last traded at $29.60, with a volume of 1331006 shares changing hands. The stock had previously closed at $26.39.

Analyst Ratings Changes

CLPT has been the topic of several research analyst reports. Stifel Nicolaus lifted their price objective on ClearPoint Neuro from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Wall Street Zen upgraded ClearPoint Neuro from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of ClearPoint Neuro in a report on Wednesday. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ClearPoint Neuro currently has a consensus rating of "Moderate Buy" and a consensus price target of $19.67.

ClearPoint Neuro Stock Up 1.3%

The stock has a market capitalization of $852.47 million, a price-to-earnings ratio of -36.45 and a beta of 1.19. The business's 50-day moving average is $13.63 and its two-hundred day moving average is $12.73. The company has a quick ratio of 6.45, a current ratio of 7.30 and a debt-to-equity ratio of 1.46.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The business had revenue of $9.22 million for the quarter, compared to analyst estimates of $9.20 million. ClearPoint Neuro had a negative return on equity of 94.44% and a negative net margin of 66.15%. ClearPoint Neuro has set its FY 2025 guidance at EPS. Equities analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

Hedge Funds Weigh In On ClearPoint Neuro

Several institutional investors and hedge funds have recently bought and sold shares of CLPT. Millennium Management LLC boosted its position in shares of ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company's stock worth $8,813,000 after purchasing an additional 452,043 shares during the period. Geode Capital Management LLC lifted its holdings in ClearPoint Neuro by 107.3% during the 2nd quarter. Geode Capital Management LLC now owns 624,800 shares of the company's stock worth $7,461,000 after buying an additional 323,429 shares in the last quarter. Lane Generational LLC raised its holdings in shares of ClearPoint Neuro by 6.8% in the 2nd quarter. Lane Generational LLC now owns 258,427 shares of the company's stock valued at $3,086,000 after purchasing an additional 16,382 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of ClearPoint Neuro by 98.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,871 shares of the company's stock valued at $3,066,000 after purchasing an additional 127,823 shares in the last quarter. Finally, Conway Capital Management Inc. raised its holdings in shares of ClearPoint Neuro by 31.1% in the 1st quarter. Conway Capital Management Inc. now owns 211,325 shares of the company's stock valued at $2,513,000 after purchasing an additional 50,100 shares in the last quarter. 30.08% of the stock is currently owned by institutional investors and hedge funds.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.